A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
NCT ID: NCT00118768
Last Updated: 2009-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
175 participants
INTERVENTIONAL
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
NCT00120835
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
NCT00120861
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
NCT00395421
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
NCT00987337
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
NCT01297270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
valopicitabine
Pegylated Interferon Alfa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment Naive (patient has received no previous treatment for chronic hepatitis C infection)
Exclusion Criteria
* Patient is co-infected with HIV or Hepatitis B
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
San Diego, California, United States
San Mateo, California, United States
Lakewood, Colorado, United States
Bradenton, Florida, United States
Gainesville, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Laurel, Maryland, United States
Worcester, Massachusetts, United States
Detroit, Michigan, United States
Kansas City, Missouri, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Germantown, Tennessee, United States
San Antonio, Texas, United States
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NV-08A-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.